• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·004310.KS
Share

Hyundai Pharmaceutical Co., Ltd. Stocks

₩ 8860Last Updated 23.09.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

₩ 170.02M

₩ 8860
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Seoul, South Korea, Hyundai Pharmaceutical Co., Ltd. is an international manufacturer and distributor of a diverse portfolio that includes pharmaceutical products, health food beverages, and medical equipment. The company's extensive offerings comprise both prescription (ETC) and over-the-counter (OTC) remedies, addressing a broad spectrum of therapeutic areas. These encompass conditions related to cardiovascular health, infectious diseases, the central nervous system, pain management, respiratory ailments, dermatological issues, digestive and endocrine system disorders, gynecological health, and ophthalmic care. Additionally, their range extends to nutritional supplements, diagnostic reagents, wound healing solutions, and treatments for allergies, arthritis, and anemia, among many others. The company was founded in 1965.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.09.2026 14:28

Is the small-cap rally coming to an end? 4 rules for picking stocks as the Fed raises rates

23.09.2026 14:02

Shares of Chinese AI developers fell following reports of an investigation into DeepSeek and Moonshot

23.09.2026 13:32

Apollo has restricted withdrawals from its private lending fund for the third consecutive time

23.09.2026 13:01

The crisis involving investment funds in Turkey is not over yet. What should investors keep an eye on?

23.09.2026 12:31

Oil is heading for its longest losing streak of the year. Traders' bets on a decline are at a peak.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026